ARCHIVES

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

Radiation, Tamoxifen After Surgery Reduce Breast Cancer Occurrence

March 25, 2011

Centers Eligible For Comprehensive Identification Names; Rauscher To Pick Four Now, Two More Later

May 24, 1974

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997

CTI Files Appeal Over FDA’s Decision on Pixantrone

December 3, 2010

NCI Eases Some Cooperative Group Concern; DeVita Considers Other CCOP- Research Base Funding Option

April 2, 1982

Bypass Budget for FY 1989 to Ask $2 Billion For NCI, With Projection To $3 Billion by 1993

May 29, 1987